{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:03:31Z","timestamp":1792692211421,"version":"4.5.0"},"reference-count":226,"publisher":"Innovative Healthcare Institute","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Immunoglobulins (Igs) are produced by B lymphocytes and play a key role in humoral immunity. Igs are classified into five isotypes (IgG, IgA, IgM, IgE, and IgD). Their primary function is to recognize and bind to foreign antigens. When Igs bind to antigens, they facilitate phagocytosis and promote clearance mediated by other immune cells. It is an essential component in protecting the host from outside pathogens. Hypogammaglobulinemia predisposes an individual to severe and recurrent infections. Therefore, replacement therapy is recommended to maintain optimal Ig level. In addition, Igs can modulate immune responses by to neutralizing proteins such as endotoxins or receptor-binding antibodies. They can be used to manage excessive immune reactions and autoimmune-related diseases. In this review, we aimed to summarize the clinical indications for Ig therapy for practicing oncologists.<\/jats:p>","DOI":"10.36401\/jipo-24-7","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T19:01:01Z","timestamp":1733338861000},"page":"34-46","source":"Crossref","is-referenced-by-count":9,"title":["Use of Immunoglobulin Replacement Therapy in Clinical Practice: A Review"],"prefix":"10.36401","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3412-7689","authenticated-orcid":true,"given":"Jibran","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonjoo","family":"Choi","sequence":"additional","affiliation":[{"name":"College of Medicine, Seoul National University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeyeong","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Medicine, Charleston Area Medical Center, Charleston, WV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-1043","authenticated-orcid":true,"given":"Joud","family":"Hajjar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Immunology, Allergy and Retrovirology, Baylor College of Medicine, Houston, TX, USA"},{"name":"The William T. Shearer Center for Immunology at Texas Children\u2019s Hospital, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","reference":[{"key":"i2590-017X-8-1-34-b01","series-title":"Blood","first-page":"1727","article-title":"Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation","volume":"115","author":"Aubin","year":"2010","unstructured":"Aubin\n              \u00c9,\n            \n            \n              Lemieux\n              R,\n            \n            \n              Bazin\n              R.\n            \n          \n          Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood. 2010;115:1727\u20131734."},{"key":"i2590-017X-8-1-34-b02","series-title":"Front Immunol","first-page":"4","article-title":"Intravenous immunoglobulin and immunomodulation of B-cell\u2013in vitro and in vivo effects","volume":"6","author":"Mitrevski","year":"2015","unstructured":"Mitrevski\n              M,\n            \n            \n              Marrapodi\n              R,\n            \n            \n              Camponeschi\n              A,\n            \n            et al.\n          \n          Intravenous immunoglobulin and immunomodulation of B-cell\u2013in vitro and in vivo effects. Front Immunol. 2015;6:4."},{"key":"i2590-017X-8-1-34-b03","article-title":"Eight guiding principles for effective use of IVIG for patients with primary immunodeficiency","author":"American Academy of Allergy, Asthma, and Immunology","year":"2011","unstructured":"American Academy of Allergy, Asthma, and Immunology\n          . Eight guiding principles for effective use of IVIG for patients with primary immunodeficiency. 2011. Accessed Oct 1, 2024. www.aaaai.org\/Aaaai\/media\/Media-Library-PDFs\/Practice%20Management\/Practice%20Tools\/IVIG-guiding-principles.pdf"},{"key":"i2590-017X-8-1-34-b04","series-title":"J Clin Immunol","first-page":"1473","article-title":"Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee","volume":"42","author":"Tangye","year":"2022","unstructured":"Tangye\n              SG,\n            \n            \n              Al-Herz\n              W,\n            \n            \n              Bousfiha\n              A,\n            \n            et al.\n          \n          Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2022;42:1473\u2013507."},{"key":"i2590-017X-8-1-34-b05","series-title":"Front Immunol","first-page":"780134","article-title":"Implementation of early next-generation sequencing for inborn errors of immunity: a prospective observational cohort study of diagnostic yield and clinical implications in Dutch genome diagnostic centers","volume":"12","author":"Elsink","year":"2021","unstructured":"Elsink\n              K,\n            \n            \n              Huibers\n              MM,\n            \n            \n              Hollink\n              IH,\n            \n            et al.\n          \n          Implementation of early next-generation sequencing for inborn errors of immunity: a prospective observational cohort study of diagnostic yield and clinical implications in Dutch genome diagnostic centers. Front Immunol. 2021;12:780134."},{"key":"i2590-017X-8-1-34-b06","series-title":"J Clin Med","first-page":"4220","article-title":"Diagnostic challenges in patients with inborn errors of immunity with different manifestations of immune dysregulation","volume":"11","author":"Pieniawska-\u015amiech","year":"2022","unstructured":"Pieniawska-\u015amiech\n              K,\n            \n            \n              Pasternak\n              G,\n            \n            \n              Lewandowicz-Uszy\u0144ska\n              A,\n            \n            \n              Jutel\n              M.\n            \n          \n          Diagnostic challenges in patients with inborn errors of immunity with different manifestations of immune dysregulation. J Clin Med. 2022;11:4220."},{"key":"i2590-017X-8-1-34-b07","series-title":"J Clin Immunol","first-page":"727","article-title":"Helicobacter bilis-associated suppurative cholangitis in a patient with X-linked agammaglobulinemia","volume":"37","author":"Degand","year":"2017","unstructured":"Degand\n              N,\n            \n            \n              Dautremer\n              J,\n            \n            \n              Pilmis\n              B,\n            \n            et al.\n          \n          \n            Helicobacter bilis-associated suppurative cholangitis in a patient with X-linked agammaglobulinemia. J Clin Immunol. 2017;37:727\u2013731."},{"key":"i2590-017X-8-1-34-b08","series-title":"Clin Immunol","first-page":"21","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","unstructured":"Orange\n              JS,\n            \n            \n              Grossman\n              WJ,\n            \n            \n              Navickis\n              RJ,\n            \n            \n              Wilkes\n              MM.\n            \n          \n          Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21\u201330."},{"key":"i2590-017X-8-1-34-b09","series-title":"Ann Intern Med","first-page":"165","article-title":"The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial","volume":"135","author":"Eijkhout","year":"2001","unstructured":"Eijkhout\n              HW,\n            \n            \n              van der Meer\n              JW,\n            \n            \n              Kallenberg\n              CG,\n            \n            et al.\n          \n          The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001;135:165\u2013174."},{"key":"i2590-017X-8-1-34-b10","series-title":"J Allergy Clin Immunol","first-page":"210","article-title":"Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection","volume":"122","author":"Bonagura","year":"2008","unstructured":"Bonagura\n              VR,\n            \n            \n              Marchlewski\n              R,\n            \n            \n              Cox\n              A,\n            \n            \n              Rosenthal\n              DW.\n            \n          \n          Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122:210\u2013212."},{"key":"i2590-017X-8-1-34-b11","series-title":"J Clin Immunol","first-page":"1468","article-title":"A registry study of 240 patients with X-linked agammaglobulinemia living in the USA","volume":"43","author":"Hernandez-Trujillo","year":"2023","unstructured":"Hernandez-Trujillo\n              V,\n            \n            \n              Zhou\n              C,\n            \n            \n              Scalchunes\n              C,\n            \n            et al.\n          \n          A registry study of 240 patients with X-linked agammaglobulinemia living in the USA. J Clin Immunol. 2023;43:1468\u20131477."},{"key":"i2590-017X-8-1-34-b12","series-title":"Curr Opin Immunol","first-page":"176","article-title":"There is no gene for CVID\u2014novel monogenetic causes for primary antibody deficiency","volume":"72","author":"Ramirez","year":"2021","unstructured":"Ramirez\n              NJ,\n            \n            \n              Posadas-Cantera\n              S,\n            \n            \n              Caballero-Oteyza\n              A,\n            \n            et al.\n          \n          There is no gene for CVID\u2014novel monogenetic causes for primary antibody deficiency. Curr Opin Immunol. 2021;72:176\u2013185."},{"key":"i2590-017X-8-1-34-b13","series-title":"J Pediatr","first-page":"888","article-title":"Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation","volume":"154","author":"Urschel","year":"2009","unstructured":"Urschel\n              S,\n            \n            \n              Kayikci\n              L,\n            \n            \n              Wintergerst\n              U,\n            \n            et al.\n          \n          Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation. J Pediatr. 2009;154:888\u2013894."},{"key":"i2590-017X-8-1-34-b14","series-title":"Front Immunol","first-page":"637","article-title":"Persistent immune activation in CVID and the role of IVIg in its suppression","volume":"5","author":"Paquin-Proulx","year":"2014","unstructured":"Paquin-Proulx\n              D,\n            \n            \n              Sandberg\n              JK.\n            \n          \n          Persistent immune activation in CVID and the role of IVIg in its suppression. Front Immunol. 2014;5:637."},{"key":"i2590-017X-8-1-34-b15","series-title":"J Allergy Clin Immunol","first-page":"1354","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years","volume":"125","author":"Lucas","year":"2010","unstructured":"Lucas\n              M,\n            \n            \n              Lee\n              M,\n            \n            \n              Lortan\n              J,\n            \n            et al.\n          \n          Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125:1354\u20131360.e4."},{"key":"i2590-017X-8-1-34-b16","series-title":"Clin Exp Immunol","first-page":"172","article-title":"Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy","volume":"169","author":"Orange","year":"2012","unstructured":"Orange\n              J,\n            \n            \n              Belohradsky\n              B,\n            \n            \n              Berger\n              M,\n            \n            et al.\n          \n          Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169:172\u2013181."},{"key":"i2590-017X-8-1-34-b17","series-title":"Blood","first-page":"2718","article-title":"Immune reconstitution and survival of 100 SCID patients post\u2013hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","unstructured":"Heimall\n              J,\n            \n            \n              Logan\n              BR,\n            \n            \n              Cowan\n              MJ,\n            \n            et al.\n          \n          Immune reconstitution and survival of 100 SCID patients post\u2013hematopoietic cell transplant: a PIDTC natural history study. Blood. 2017;130:2718\u20132727."},{"key":"i2590-017X-8-1-34-b18","series-title":"Cell","first-page":"565","article-title":"Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)","volume":"102","author":"Revy","year":"2000","unstructured":"Revy\n              P,\n            \n            \n              Muto\n              T,\n            \n            \n              Levy\n              Y,\n            \n            et al.\n          \n          Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000;102:565\u2013575."},{"key":"i2590-017X-8-1-34-b19","series-title":"J Trop Pediatr","first-page":"648","article-title":"X-linked hyper IgM syndrome manifesting as recurrent Pneumocystis jirovecii pneumonia: a case report","volume":"66","author":"Huang","year":"2020","unstructured":"Huang\n              SH,\n            \n            \n              Meng\n              XY,\n            \n            \n              Bai\n              ZJ,\n            \n            et al.\n          \n          X-linked hyper IgM syndrome manifesting as recurrent Pneumocystis jirovecii pneumonia: a case report. J Trop Pediatr. 2020;66:648\u2013654."},{"key":"i2590-017X-8-1-34-b20","series-title":"J Allergy Clin Immunol Pract","first-page":"1023","article-title":"Clinical phenotypes of hyper-IgM syndromes","volume":"4","author":"de la Morena","year":"2016","unstructured":"de la Morena\n              MT.\n            \n          \n          Clinical phenotypes of hyper-IgM syndromes. J Allergy Clin Immunol Pract. 2016;4:1023\u20131036."},{"key":"i2590-017X-8-1-34-b21","series-title":"Placenta","first-page":"36","article-title":"Expression of the neonatal Fc-receptor in placental-fetal endothelium and in cells of the placental immune system","volume":"78","author":"Kiskova","year":"2019","unstructured":"Kiskova\n              T,\n            \n            \n              Mytsko\n              Y,\n            \n            \n              Schepelmann\n              M,\n            \n            et al.\n          \n          Expression of the neonatal Fc-receptor in placental-fetal endothelium and in cells of the placental immune system. Placenta. 2019;78:36\u201343."},{"key":"i2590-017X-8-1-34-b22","series-title":"J Perinatol","first-page":"929","article-title":"Hypogammaglobulinemia in neonates: illustrative cases and review of the literature","volume":"44","author":"Darmawan","year":"2023","unstructured":"Darmawan\n              D,\n            \n            \n              Raychaudhuri\n              S,\n            \n            \n              Lakshminrusimha\n              S,\n            \n            \n              Dimitriades\n              VR.\n            \n          \n          Hypogammaglobulinemia in neonates: illustrative cases and review of the literature. J Perinatol. 2023;44:929\u2013934."},{"key":"i2590-017X-8-1-34-b23","author":"Justiz Vaillant","year":"2021","unstructured":"Justiz Vaillant\n              AA,\n            \n            \n              Wilson\n              AM.\n            \n          \n          Transient Hypogammaglobulinemia of Infancy. StatPearls Publishing; 2021."},{"key":"i2590-017X-8-1-34-b24","series-title":"Pediatr Rep","first-page":"e14","article-title":"Does intravenous immunoglobulin therapy prolong immunodeficiency in transient hypogammaglobulinemia of infancy","volume":"5","author":"Memmedova","year":"2013","unstructured":"Memmedova\n              L,\n            \n            \n              Azarsiz\n              E,\n            \n            \n              Karaca\n              NE,\n            \n            et al.\n          \n          Does intravenous immunoglobulin therapy prolong immunodeficiency in transient hypogammaglobulinemia of infancy? Pediatr Rep. 2013;5:e14."},{"key":"i2590-017X-8-1-34-b25","series-title":"J Clin Immunol","first-page":"158","article-title":"Prophylactic antibiotics versus immunoglobulin replacement in specific antibody deficiency","volume":"40","author":"Joud","year":"2020","unstructured":"Joud\n              H,\n            \n            \n              Nguyen\n              AL,\n            \n            \n              Constantine\n              G,\n            \n            et al.\n          \n          Prophylactic antibiotics versus immunoglobulin replacement in specific antibody deficiency. J Clin Immunol. 2020;40:158\u2013164."},{"key":"i2590-017X-8-1-34-b26","series-title":"J Clin Immunol","first-page":"382","article-title":"Immunoglobulin replacement therapy versus antibiotic prophylaxis as treatment for incomplete primary antibody deficiency","volume":"41","author":"Smits","year":"2021","unstructured":"Smits\n              BM,\n            \n            \n              Kleine Budde\n              I,\n            \n            \n              de Vries\n              E,\n            \n            et al.\n          \n          Immunoglobulin replacement therapy versus antibiotic prophylaxis as treatment for incomplete primary antibody deficiency. J Clin Immunol. 2021;41:382\u2013392."},{"key":"i2590-017X-8-1-34-b27","series-title":"Scand J Infect Dis","first-page":"44","article-title":"Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up","volume":"39","author":"Olinder-Nielsen","year":"2007","unstructured":"Olinder-Nielsen\n              AM,\n            \n            \n              Granert\n              C,\n            \n            \n              Forsberg\n              P,\n            \n            et al.\n          \n          Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up. Scand J Infect Dis. 2007;39:44\u201350."},{"issue":"2 Suppl 2","key":"i2590-017X-8-1-34-b28","series-title":"J Allergy Clin Immunol","first-page":"S195","article-title":"Secondary immunodeficiencies, including HIV infection","volume":"125","author":"Chinen","year":"2010","unstructured":"Chinen\n              J,\n            \n            \n              Shearer\n              WT.\n            \n          \n          Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S195\u2013S203."},{"key":"i2590-017X-8-1-34-b29","series-title":"Haematologica","first-page":"107","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","unstructured":"Blimark\n              C,\n            \n            \n              Holmberg\n              E,\n            \n            \n              Mellqvist\n              UH,\n            \n            et al.\n          \n          Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107\u2013113."},{"key":"i2590-017X-8-1-34-b30","series-title":"BMC Cancer","first-page":"1","article-title":"Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019","volume":"21","author":"Balmaceda","year":"2021","unstructured":"Balmaceda\n              N,\n            \n            \n              Aziz\n              M,\n            \n            \n              Chandrasekar\n              VT,\n            \n            et al.\n          \n          Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer. 2021;21:1\u201311."},{"key":"i2590-017X-8-1-34-b31","series-title":"Leukemia","first-page":"613","article-title":"Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients","volume":"36","author":"Caro","year":"2022","unstructured":"Caro\n              J,\n            \n            \n              Braunstein\n              M,\n            \n            \n              Williams\n              L,\n            \n            et al.\n          \n          Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. Leukemia. 2022;36:613\u2013624."},{"key":"i2590-017X-8-1-34-b32","series-title":"Blood Adv","first-page":"5898","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","unstructured":"Reynolds\n              G,\n            \n            \n              Cliff\n              ERS,\n            \n            \n              Mohyuddin\n              GR,\n            \n            et al.\n          \n          Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7:5898\u20135903."},{"key":"i2590-017X-8-1-34-b33","series-title":"Lancet","first-page":"1059","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma","volume":"343","author":"Chapel","year":"1994","unstructured":"Chapel\n              HM,\n            \n            \n              Lee\n              M,\n            \n            \n              Hargreaves\n              R,\n            \n            et al.\n          \n          Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet. 1994;343:1059\u20131063."},{"key":"i2590-017X-8-1-34-b34","series-title":"Leuk Lymphoma","first-page":"764","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","unstructured":"Raanani\n              P,\n            \n            \n              Gafter-Gvili\n              A,\n            \n            \n              Paul\n              M,\n            \n            et al.\n          \n          Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009;50:764\u2013772."},{"key":"i2590-017X-8-1-34-b35","series-title":"Lancet Haematol","first-page":"e143","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","unstructured":"Raje\n              NS,\n            \n            \n              Anaissie\n              E,\n            \n            \n              Kumar\n              SK,\n            \n            et al.\n          \n          Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9:e143\u2013e61."},{"key":"i2590-017X-8-1-34-b36","series-title":"Front Immunol","first-page":"1299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","unstructured":"Guo\n              Y,\n            \n            \n              Tian\n              X,\n            \n            \n              Wang\n              X,\n            \n            \n              Xiao\n              Z.\n            \n          \n          Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299."},{"key":"i2590-017X-8-1-34-b37","series-title":"Transpl Infect Dis","first-page":"679","article-title":"Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma","volume":"17","author":"Park","year":"2015","unstructured":"Park\n              S,\n            \n            \n              Jung\n              CW,\n            \n            \n              Jang\n              JH,\n            \n            et al.\n          \n          Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma. Transpl Infect Dis. 2015;17:679\u2013687."},{"key":"i2590-017X-8-1-34-b38","series-title":"Blood Cancer J","first-page":"116","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","unstructured":"Raje\n              N,\n            \n            \n              Anderson\n              K,\n            \n            \n              Einsele\n              H,\n            \n            et al.\n          \n          Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13:116."},{"key":"i2590-017X-8-1-34-b39","series-title":"Leuk Lymphoma","first-page":"18","article-title":"Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule","volume":"64","author":"Sim","year":"2023","unstructured":"Sim\n              B,\n            \n            \n              Ng\n              JY,\n            \n            \n              Teh\n              BW,\n            \n            \n              Talaulikar\n              D.\n            \n          \n          Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule. Leuk Lymphoma. 2023;64:18\u201329."},{"key":"i2590-017X-8-1-34-b40","series-title":"Curr Oncol Rep","first-page":"1003","article-title":"Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies","volume":"24","author":"Rivera","year":"2022","unstructured":"Rivera\n              D,\n            \n            \n              Ferrajoli\n              A.\n            \n          \n          Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies. Curr Oncol Rep. 2022;24:1003\u20131014."},{"key":"i2590-017X-8-1-34-b41","series-title":"Br J Haematol","first-page":"541","article-title":"Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia","volume":"159","author":"Oscier","year":"2012","unstructured":"Oscier\n              D,\n            \n            \n              Dearden\n              C,\n            \n            \n              Eren\n              E,\n            \n            et al.\n          \n          Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159:541\u2013564."},{"key":"i2590-017X-8-1-34-b42","series-title":"Hematol Transfus Cell Ther","first-page":"387","article-title":"Infections in patients with chronic lymphocytic leukemia","volume":"45","author":"Guarana","year":"2023","unstructured":"Guarana\n              M,\n            \n            \n              Nucci\n              M.\n            \n          \n          Infections in patients with chronic lymphocytic leukemia. Hematol Transfus Cell Ther. 2023;45:387\u2013393."},{"key":"i2590-017X-8-1-34-b43","series-title":"Cancer","first-page":"2883","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","unstructured":"Parikh\n              SA,\n            \n            \n              Leis\n              JF,\n            \n            \n              Chaffee\n              KG,\n            \n            et al.\n          \n          Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer. 2015;121:2883\u20132891."},{"key":"i2590-017X-8-1-34-b44","series-title":"N Engl J Med","first-page":"902","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial","volume":"319","author":"Gale","year":"1988","unstructured":"Gale\n              RP,\n            \n            \n              Chapel\n              HM,\n            \n            \n              Bunch\n              C,\n            \n            et al.\n          \n          Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319:902\u2013907."},{"key":"i2590-017X-8-1-34-b45","series-title":"N Engl J Med","first-page":"902","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial","volume":"319","author":"Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia","year":"1988","unstructured":"Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia, GaleRP,ChapelHM,et al.\n          Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319:902\u2013907."},{"key":"i2590-017X-8-1-34-b46","series-title":"Front Immunol","first-page":"317","article-title":"Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy","volume":"7","author":"S\u00e1nchez-Ram\u00f3n","year":"2016","unstructured":"S\u00e1nchez-Ram\u00f3n\n              S,\n            \n            \n              Dhalla\n              F,\n            \n            \n              Chapel\n              H.\n            \n          \n          Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy. Front Immunol. 2016;7:317."},{"key":"i2590-017X-8-1-34-b47","series-title":"Blood","first-page":"2745","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","unstructured":"Hallek\n              M,\n            \n            \n              Cheson\n              BD,\n            \n            \n              Catovsky\n              D,\n            \n            et al.\n          \n          iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u20132760."},{"key":"i2590-017X-8-1-34-b48","series-title":"Front Oncol","first-page":"1135812","article-title":"An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies","volume":"13","author":"Khan","year":"2023","unstructured":"Khan\n              S,\n            \n            \n              Allsup\n              D,\n            \n            \n              Molica\n              S.\n            \n          \n          An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies. Front Oncol. 2023;13:1135812."},{"key":"i2590-017X-8-1-34-b49","series-title":"Hematol Oncol Clin North Am","first-page":"827","article-title":"Can immunocompetence be restored in chronic lymphocytic leukemia","volume":"35","author":"Sun","year":"2021","unstructured":"Sun\n              C,\n            \n            \n              Wiestner\n              A.\n            \n          \n          Can immunocompetence be restored in chronic lymphocytic leukemia? Hematol Oncol Clin North Am. 2021;35:827\u2013845."},{"key":"i2590-017X-8-1-34-b50","series-title":"J Allergy Clin Immunol","first-page":"1525","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees","volume":"149","author":"Otani","year":"2022","unstructured":"Otani\n              IM,\n            \n            \n              Lehman\n              HK,\n            \n            \n              Jongco\n              AM,\n            \n            et al.\n          \n          Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees. J Allergy Clin Immunol. 2022;149:1525\u20131560."},{"key":"i2590-017X-8-1-34-b51","series-title":"Indian J Hematol Blood Transfus","first-page":"282","article-title":"Secondary hypogammaglobulinemia in patients with chronic lymphocytic leukemia receiving ibrutinib therapy","volume":"38","author":"\u00c7elik","year":"2022","unstructured":"\u00c7elik\n              S,\n            \n            \n              Kaynar\n              L,\n            \n            \n              G\u00fcven\n              ZT,\n            \n            et al.\n          \n          Secondary hypogammaglobulinemia in patients with chronic lymphocytic leukemia receiving ibrutinib therapy. Indian J Hematol Blood Transfus. 2022;38:282\u2013289."},{"key":"i2590-017X-8-1-34-b52","series-title":"Curr Oncol","first-page":"274","article-title":"A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and secondary antibody deficiency","volume":"30","author":"Visentin","year":"2022","unstructured":"Visentin\n              A,\n            \n            \n              Molinari\n              MC,\n            \n            \n              Pravato\n              S,\n            \n            et al.\n          \n          A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and secondary antibody deficiency. Curr Oncol. 2022;30:274\u2013283."},{"key":"i2590-017X-8-1-34-b53","series-title":"Immunotherapy","first-page":"713","article-title":"Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution","volume":"10","author":"Sacco","year":"2018","unstructured":"Sacco\n              KA,\n            \n            \n              Abraham\n              RS.\n            \n          \n          Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy. 2018;10:713\u2013728."},{"key":"i2590-017X-8-1-34-b54","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"106","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","unstructured":"Casulo\n              C,\n            \n            \n              Maragulia\n              J,\n            \n            \n              Zelenetz\n              AD.\n            \n          \n          Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13:106\u2013111."},{"key":"i2590-017X-8-1-34-b55","series-title":"J Allergy Clin Immunol","first-page":"1332","article-title":"Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations","volume":"148","author":"Thalhammer","year":"2021","unstructured":"Thalhammer\n              J,\n            \n            \n              Kindle\n              G,\n            \n            \n              Nieters\n              A,\n            \n            et al.\n          \n          Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. J Allergy Clin Immunol. 2021;148:1332\u20131341.e5."},{"key":"i2590-017X-8-1-34-b56","series-title":"JAMA Netw Open","first-page":"e184169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","unstructured":"Barmettler\n              S,\n            \n            \n              Ong\n              MS,\n            \n            \n              Farmer\n              JR,\n            \n            et al.\n          \n          Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1:e184169."},{"key":"i2590-017X-8-1-34-b57","series-title":"J Autoimmun","first-page":"24","article-title":"Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series","volume":"57","author":"Roberts","year":"2015","unstructured":"Roberts\n              DM,\n            \n            \n              Jones\n              RB,\n            \n            \n              Smith\n              RM,\n            \n            et al.\n          \n          Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun. 2015;57:24\u201329."},{"key":"i2590-017X-8-1-34-b58","series-title":"J Allergy Clin Immunol Pract","first-page":"460","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","unstructured":"Wat\n              J,\n            \n            \n              Barmettler\n              S.\n            \n          \n          Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions. J Allergy Clin Immunol Pract. 2022;10:460\u2013466."},{"key":"i2590-017X-8-1-34-b59","series-title":"Expert Rev Hematol","first-page":"305","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians","volume":"15","author":"Kampouri","year":"2022","unstructured":"Kampouri\n              E,\n            \n            \n              Walti\n              CS,\n            \n            \n              Gauthier\n              J,\n            \n            \n              Hill\n              JA.\n            \n          \n          Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Rev Hematol. 2022;15:305\u2013320."},{"key":"i2590-017X-8-1-34-b60","series-title":"Blood Adv","first-page":"2525","article-title":"Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1","volume":"3","author":"Ustun","year":"2019","unstructured":"Ustun\n              C,\n            \n            \n              Kim\n              S,\n            \n            \n              Chen\n              M,\n            \n            et al.\n          \n          Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. Blood Adv. 2019;3:2525\u20132536."},{"key":"i2590-017X-8-1-34-b61","series-title":"Blood","first-page":"3928","article-title":"The risk factors for IgG hypogammaglobulinemia after allogeneic hematopoietic stem cell transplantation and its impact on transplant outcomes","volume":"124","author":"Uhm","year":"2014","unstructured":"Uhm\n              J,\n            \n            \n              Hamad\n              N,\n            \n            \n              Gupta\n              V,\n            \n            et al.\n          \n          The risk factors for IgG hypogammaglobulinemia after allogeneic hematopoietic stem cell transplantation and its impact on transplant outcomes. Blood. 2014;124:3928."},{"key":"i2590-017X-8-1-34-b62","series-title":"Int J Hematol","first-page":"422","article-title":"Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy","volume":"112","author":"Mizuhara","year":"2020","unstructured":"Mizuhara\n              K,\n            \n            \n              Fujii\n              N,\n            \n            \n              Meguri\n              Y,\n            \n            et al.\n          \n          Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy. Int J Hematol. 2020;112:422\u2013426."},{"key":"i2590-017X-8-1-34-b63","series-title":"Bone Marrow Transplant","first-page":"267","article-title":"Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival","volume":"41","author":"Norlin","year":"2008","unstructured":"Norlin\n              A,\n            \n            \n              Sairafi\n              D,\n            \n            \n              Mattsson\n              J,\n            \n            et al.\n          \n          Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant. 2008;41:267\u2013273."},{"issue":"Suppl 1","key":"i2590-017X-8-1-34-b64","series-title":"Clin Exp Immunol","first-page":"43","article-title":"Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease","volume":"104","author":"Sullivan","year":"1996","unstructured":"Sullivan\n              KM.\n            \n          \n          Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. Clin Exp Immunol. 1996;104(Suppl 1):43\u201348."},{"issue":"Suppl 1","key":"i2590-017X-8-1-34-b65","series-title":"Clin Exp Immunol","first-page":"94","article-title":"Intravenous immunoglobulin and immune response","volume":"178","author":"Kaveri","year":"2014","unstructured":"Kaveri\n              S,\n            \n            \n              Lecerf\n              M,\n            \n            \n              Saha\n              C,\n            \n            et al.\n          \n          Intravenous immunoglobulin and immune response. Clin Exp Immunol. 2014;178(Suppl 1):94."},{"key":"i2590-017X-8-1-34-b66","series-title":"N Engl J Med","first-page":"2565","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","unstructured":"Zeiser\n              R,\n            \n            \n              Blazar\n              BR.\n            \n          \n          Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565\u20132579."},{"key":"i2590-017X-8-1-34-b67","series-title":"Front Immunol","first-page":"578314","article-title":"New approaches for the treatment of chronic graft-versus-host disease: current status and future directions","volume":"11","author":"Saidu","year":"2020","unstructured":"Saidu\n              NEB,\n            \n            \n              Bonini\n              C,\n            \n            \n              Dickinson\n              A,\n            \n            et al.\n          \n          New approaches for the treatment of chronic graft-versus-host disease: current status and future directions. Front Immunol. 2020;11:578314."},{"key":"i2590-017X-8-1-34-b68","series-title":"J Natl Compr Canc Netw","first-page":"599","article-title":"Hematopoietic cell transplantation, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Saad","year":"2020","unstructured":"Saad\n              A,\n            \n            \n              de Lima\n              M,\n            \n            \n              Anand\n              S,\n            \n            et al.\n          \n          Hematopoietic cell transplantation, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:599\u2013634."},{"key":"i2590-017X-8-1-34-b69","series-title":"Am J Transplant","first-page":"1157","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","unstructured":"Wiebe\n              C,\n            \n            \n              Gibson\n              I,\n            \n            \n              Blydt-Hansen\n              T,\n            \n            et al.\n          \n          Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157\u20131167."},{"key":"i2590-017X-8-1-34-b70","series-title":"Transplantation","first-page":"887","article-title":"Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients","volume":"70","author":"Montgomery","year":"2000","unstructured":"Montgomery\n              RA,\n            \n            \n              Zachary\n              AA,\n            \n            \n              Racusen\n              LC,\n            \n            et al.\n          \n          Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70:887\u2013895."},{"key":"i2590-017X-8-1-34-b71","series-title":"Sci Rep","first-page":"7682","article-title":"Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients","volume":"13","author":"Kim","year":"2023","unstructured":"Kim\n              HW,\n            \n            \n              Lee\n              J,\n            \n            \n              Heo\n              S-J,\n            \n            et al.\n          \n          Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients. Sci Rep. 2023;13:7682."},{"key":"i2590-017X-8-1-34-b72","series-title":"Am J Transplant","first-page":"255","article-title":"Diagnosis and management of antibody-mediated rejection: current status and novel approaches","volume":"14","author":"Djamali","year":"2014","unstructured":"Djamali\n              A,\n            \n            \n              Kaufman\n              D,\n            \n            \n              Ellis\n              T,\n            \n            et al.\n          \n          Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant. 2014;14:255\u2013271."},{"key":"i2590-017X-8-1-34-b73","series-title":"Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection: A Review of Clinical Effectiveness. CADTH Rapid Response Reports","author":"Khangura","year":"2018","unstructured":"Khangura\n              SD,\n            \n            \n              Visintini\n              S.\n            \n          \n          \n            Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection: A Review of Clinical Effectiveness. CADTH Rapid Response Reports\n          . Ottawa, Ontario, Canada: Canadian Agency for Drugs and Technologies in Health; 2018."},{"issue":"Suppl 1","key":"i2590-017X-8-1-34-b74","series-title":"Transfus Med Rev","first-page":"S1","article-title":"Guidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation","volume":"24","author":"Nahirniak","year":"2010","unstructured":"Nahirniak\n              S,\n            \n            \n              Hume\n              HA.\n            \n          \n          Guidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation. Transfus Med Rev. 2010;24(Suppl 1):S1\u2013S6."},{"key":"i2590-017X-8-1-34-b75","series-title":"BMC Nephrology","first-page":"218","article-title":"Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection","volume":"20","author":"Sablik","year":"2019","unstructured":"Sablik\n              KA,\n            \n            \n              Clahsen-van Groningen\n              MC,\n            \n            \n              Looman\n              CWN,\n            \n            et al.\n          \n          Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection. BMC Nephrology. 2019;20:218."},{"issue":"1","key":"i2590-017X-8-1-34-b76","series-title":"BMC Nephrology","first-page":"9","article-title":"Treatment of chronic active antibody-mediated rejection in renal transplant recipients\u2013a single center retrospective study","volume":"21","author":"Chiu","year":"2020","unstructured":"Chiu\n              H-F,\n            \n            \n              Wen\n              M-C,\n            \n            \n              Wu\n              M-J,\n            \n            et al.\n          \n          Treatment of chronic active antibody-mediated rejection in renal transplant recipients\u2013a single center retrospective study. BMC Nephrology. 2020;21:1\u20139."},{"key":"i2590-017X-8-1-34-b77","series-title":"N Engl J Med","first-page":"945","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","unstructured":"Cooper\n              N,\n            \n            \n              Ghanima\n              W.\n            \n          \n          Immune thrombocytopenia. N Engl J Med. 2019;381:945\u2013955."},{"key":"i2590-017X-8-1-34-b78","series-title":"Lancet","first-page":"1228","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","unstructured":"Imbach\n              P,\n            \n            \n              Barandun\n              S,\n            \n            \n              d\u2019Apuzzo\n              V,\n            \n            et al.\n          \n          High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228\u20131231."},{"key":"i2590-017X-8-1-34-b79","series-title":"Transfus Med","first-page":"48","article-title":"Efficacy and safety of a new intravenous immunoglobulin (Panzyga(I)) in chronic immune thrombocytopenia","volume":"29","author":"Arbach","year":"2019","unstructured":"Arbach\n              O,\n            \n            \n              Taumberger\n              AB,\n            \n            \n              Wietek\n              S,\n            \n            et al.\n          \n          Efficacy and safety of a new intravenous immunoglobulin (Panzyga(I)) in chronic immune thrombocytopenia. Transfus Med. 2019;29:48\u201354."},{"key":"i2590-017X-8-1-34-b80","series-title":"Eur J Haematol","first-page":"531","article-title":"Autoimmune thrombocytopenia: current treatment options in adults with a focus on novel drugs","volume":"103","author":"Witkowski","year":"2019","unstructured":"Witkowski\n              M,\n            \n            \n              Witkowska\n              M,\n            \n            \n              Robak\n              T.\n            \n          \n          Autoimmune thrombocytopenia: current treatment options in adults with a focus on novel drugs. Eur J Haematol. 2019;103:531\u2013541."},{"key":"i2590-017X-8-1-34-b81","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"400","article-title":"Management of newly diagnosed immune thrombocytopenia: can we change outcomes","volume":"2017","author":"Neunert","year":"2017","unstructured":"Neunert\n              CE.\n            \n          \n          Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Hematology Am Soc Hematol Educ Program. 2017;2017:400\u2013405."},{"key":"i2590-017X-8-1-34-b82","series-title":"N Engl J Med","first-page":"647","article-title":"Warm autoimmune hemolytic anemia","volume":"381","author":"Brodsky","year":"2019","unstructured":"Brodsky\n              RA.\n            \n          \n          Warm autoimmune hemolytic anemia. N Engl J Med. 2019;381:647\u2013654."},{"key":"i2590-017X-8-1-34-b83","series-title":"Blood Rev","first-page":"100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","unstructured":"J\u00e4ger\n              U,\n            \n            \n              Barcellini\n              W,\n            \n            \n              Broome\n              CM,\n            \n            et al.\n          \n          Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648."},{"key":"i2590-017X-8-1-34-b84","series-title":"Autoimmun Rev","first-page":"264","article-title":"Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia","volume":"4","author":"Mouthon","year":"2005","unstructured":"Mouthon\n              L,\n            \n            \n              Guillevin\n              L,\n            \n            \n              Tellier\n              Z.\n            \n          \n          Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev. 2005;4:264\u2013269."},{"key":"i2590-017X-8-1-34-b85","series-title":"N Engl J Med","first-page":"519","article-title":"Pure red-cell aplasia of 10 ye\u2019rs' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy","volume":"321","author":"Kurtzman","year":"1989","unstructured":"Kurtzman\n              G,\n            \n            \n              Frickhofen\n              N,\n            \n            \n              Kimball\n              J,\n            \n            et al.\n          \n          Pure red-cell aplasia of 10 ye\u2019rs' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med. 1989;321:519\u2013523."},{"key":"i2590-017X-8-1-34-b86","series-title":"Transplantation","first-page":"1847","article-title":"Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin","volume":"64","author":"Moudgil","year":"1997","unstructured":"Moudgil\n              A,\n            \n            \n              Shidban\n              H,\n            \n            \n              Nast\n              CC,\n            \n            et al.\n          \n          Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation. 1997;64:1847\u20131850."},{"key":"i2590-017X-8-1-34-b87","series-title":"Am J Hematol","first-page":"16","article-title":"Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin\u2013a report of eight patients","volume":"61","author":"Koduri","year":"1999","unstructured":"Koduri\n              PR,\n            \n            \n              Kumapley\n              R,\n            \n            \n              Valladares\n              J,\n            \n            \n              Teter\n              C.\n            \n          \n          Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin\u2013a report of eight patients. Am J Hematol. 1999;61:16\u201320."},{"key":"i2590-017X-8-1-34-b88","series-title":"Front Med","first-page":"1208418","article-title":"Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience","volume":"10","author":"Merli","year":"2023","unstructured":"Merli\n              M,\n            \n            \n              Accorinti\n              M,\n            \n            \n              Romagnuolo\n              M,\n            \n            et al.\n          \n          Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience. Front Med. 2023;10:1208418."},{"key":"i2590-017X-8-1-34-b89","series-title":"J Immunother","first-page":"276","article-title":"Immune checkpoint inhibitor\u2013related Guillain-Barr\u00e9 syndrome: a case series and review of the literature","volume":"44","author":"Janssen","year":"2021","unstructured":"Janssen\n              JB,\n            \n            \n              Leow\n              TY,\n            \n            \n              Herbschleb\n              KH,\n            \n            et al.\n          \n          Immune checkpoint inhibitor\u2013related Guillain-Barr\u00e9 syndrome: a case series and review of the literature. J Immunother. 2021;44:276\u2013282."},{"key":"i2590-017X-8-1-34-b90","series-title":"J Immunother Cancer","first-page":"1","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","unstructured":"Safa\n              H,\n            \n            \n              Johnson\n              DH,\n            \n            \n              Trinh\n              VA,\n            \n            et al.\n          \n          Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7:1\u201311."},{"key":"i2590-017X-8-1-34-b91","series-title":"Front Immunol","first-page":"1275254","article-title":"Immune checkpoint inhibitor\u2013associated myocarditis: a systematic analysis of case reports","volume":"14","author":"Wang","year":"2023","unstructured":"Wang\n              C,\n            \n            \n              Zhao\n              G,\n            \n            \n              Zhang\n              Z,\n            \n            et al.\n          \n          Immune checkpoint inhibitor\u2013associated myocarditis: a systematic analysis of case reports. Front Immunol. 2023;14:1275254."},{"key":"i2590-017X-8-1-34-b92","series-title":"Curr Rheumatol Rep","first-page":"1","article-title":"Immune checkpoint inhibitor-induced myositis: a case report and literature review","volume":"21","author":"Kadota","year":"2019","unstructured":"Kadota\n              H,\n            \n            \n              Gono\n              T,\n            \n            \n              Shirai\n              Y,\n            \n            et al.\n          \n          Immune checkpoint inhibitor-induced myositis: a case report and literature review. Curr Rheumatol Rep. 2019;21:1\u20139."},{"key":"i2590-017X-8-1-34-b93","series-title":"J Immunother Cancer","first-page":"e002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","unstructured":"Brahmer\n              JR,\n            \n            \n              Abu-Sbeih\n              H,\n            \n            \n              Ascierto\n              PA,\n            \n            et al.\n          \n          Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:e002435."},{"key":"i2590-017X-8-1-34-b94","series-title":"Respir Med Case Rep","first-page":"100834","article-title":"Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: case report and review of the literature","volume":"27","author":"Petri","year":"2019","unstructured":"Petri\n              CR,\n            \n            \n              Patell\n              R,\n            \n            \n              Batalini\n              F,\n            \n            et al.\n          \n          Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: case report and review of the literature. Respir Med Case Rep. 2019;27:100834."},{"key":"i2590-017X-8-1-34-b95","series-title":"Anticancer Drugs","first-page":"e738","article-title":"Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis","volume":"33","author":"Kian","year":"2022","unstructured":"Kian\n              W,\n            \n            \n              Zemel\n              M,\n            \n            \n              Elobra\n              F,\n            \n            et al.\n          \n          Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis. Anticancer Drugs. 2022;33:e738\u2013e40."},{"key":"i2590-017X-8-1-34-b96","series-title":"Neurology","first-page":"419","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","unstructured":"Sanders\n              DB,\n            \n            \n              Wolfe\n              GI,\n            \n            \n              Benatar\n              M,\n            \n            et al.\n          \n          International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87:419\u2013425."},{"key":"i2590-017X-8-1-34-b97","series-title":"Ann N Y Acad Sci","first-page":"720","article-title":"Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis","volume":"841","author":"Gajdos","year":"1998","unstructured":"Gajdos\n              P,\n            \n            \n              Chevret\n              S,\n            \n            \n              Clair\n              B,\n            \n            et al.\n          \n          Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. Ann N Y Acad Sci. 1998;841:720\u2013726."},{"issue":"12","key":"i2590-017X-8-1-34-b98","series-title":"Cochrane Database Syst Rev","first-page":"CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Eftimov","year":"2013","unstructured":"Eftimov\n              F,\n            \n            \n              Winer\n              JB,\n            \n            \n              Vermeulen\n              M,\n            \n            et al.\n          \n          Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;(12):CD001797."},{"key":"i2590-017X-8-1-34-b99","series-title":"Eur J Dermatol","first-page":"90","article-title":"European Dermatology Forum Guideline Subcommittee. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology","volume":"19","author":"Enk","year":"2009","unstructured":"Enk\n              A\n            \n          , European Dermatology Forum Guideline Subcommittee. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol. 2009;19:90\u201398."},{"key":"i2590-017X-8-1-34-b100","series-title":"Int J Rheum Dis","first-page":"64","article-title":"Role of intravenous immunoglobulin in the treatment of Kawasaki disease","volume":"21","author":"Lo","year":"2018","unstructured":"Lo\n              MS,\n            \n            \n              Newburger\n              JW.\n            \n          \n          Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis. 2018;21:64\u201369."},{"key":"i2590-017X-8-1-34-b101","series-title":"J Dermatol Sci","first-page":"77","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","unstructured":"Amagai\n              M,\n            \n            \n              Ikeda\n              S,\n            \n            \n              Hashimoto\n              T,\n            \n            et al.\n          \n          A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J Dermatol Sci. 2017;85:77\u201384."},{"key":"i2590-017X-8-1-34-b102","series-title":"Ann Rheum Dis","first-page":"1583","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","unstructured":"Yates\n              M,\n            \n            \n              Watts\n              RA,\n            \n            \n              Bajema\n              I,\n            \n            et al.\n          \n          EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583\u20131594."},{"key":"i2590-017X-8-1-34-b103","series-title":"Rheumatology","first-page":"646","article-title":"Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion","volume":"47","author":"Perricone","year":"2008","unstructured":"Perricone\n              R,\n            \n            \n              De Carolis\n              C,\n            \n            \n              Kr\u00f6egler\n              B,\n            \n            et al.\n          \n          Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology. 2008;47:646\u2013651."},{"key":"i2590-017X-8-1-34-b104","series-title":"Front Immunol","first-page":"740517","article-title":"A retrospective observational study of adverse reactions associated with intravenous immunoglobulin infusion","volume":"12","author":"Kato","year":"2021","unstructured":"Kato\n              H,\n            \n            \n              Hayashi\n              M,\n            \n            \n              Ohashi\n              W,\n            \n            et al.\n          \n          A retrospective observational study of adverse reactions associated with intravenous immunoglobulin infusion. Front Immunol. 2021;12:740517."},{"key":"i2590-017X-8-1-34-b105","series-title":"Am J Health-Syst Pharm","first-page":"1415","article-title":"Immune globulin therapy and kidney disease: overview and screening, monitoring, and management recommendations","volume":"79","author":"Kobayashi","year":"2022","unstructured":"Kobayashi\n              RH,\n            \n            \n              Rigas\n              MT.\n            \n          \n          Immune globulin therapy and kidney disease: overview and screening, monitoring, and management recommendations. Am J Health-Syst Pharm. 2022;79:1415\u20131423."},{"key":"i2590-017X-8-1-34-b106","series-title":"PLoS One","first-page":"e0265852","article-title":"Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles","volume":"17","author":"Abbott","year":"2022","unstructured":"Abbott\n              JK,\n            \n            \n              Chan\n              SK,\n            \n            \n              MacBeth\n              M,\n            \n            et al.\n          \n          Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles. PLoS One. 2022;17:e0265852."},{"key":"i2590-017X-8-1-34-b107","series-title":"J Am Acad Dermatol","first-page":"AB45","article-title":"Eczematous skin reaction after intravenous immunoglobulin (IVIG) therapy","volume":"72","author":"Zhang","year":"2015","unstructured":"Zhang\n              J,\n            \n            \n              Cusack\n              CA.\n            \n          \n          Eczematous skin reaction after intravenous immunoglobulin (IVIG) therapy. J Am Acad Dermatol. 2015;72:AB45."},{"key":"i2590-017X-8-1-34-b108","series-title":"Clin Exp Immunol","first-page":"384","article-title":"Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study","volume":"206","author":"Martinez","year":"2021","unstructured":"Martinez\n              C,\n            \n            \n              Wallenhorst\n              C,\n            \n            \n              van Nunen\n              S.\n            \n          \n          Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study. Clin Exp Immunol. 2021;206:384\u2013394."},{"key":"i2590-017X-8-1-34-b109","series-title":"Clin Rheumatol","first-page":"541","article-title":"Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review","volume":"39","author":"Baudel","year":"2020","unstructured":"Baudel\n              JL,\n            \n            \n              Vigneron\n              C,\n            \n            \n              Pras-Landre\n              V,\n            \n            et al.\n          \n          Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review. Clin Rheumatol. 2020;39:541\u2013546."},{"key":"i2590-017X-8-1-34-b110","series-title":"Autoimmun Rev","first-page":"71","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence","volume":"15","author":"Cherin","year":"2016","unstructured":"Cherin\n              P,\n            \n            \n              Marie\n              I,\n            \n            \n              Michallet\n              M,\n            \n            et al.\n          \n          Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15:71\u201381."},{"issue":"2","key":"i2590-017X-8-1-34-b111","series-title":"J Allergy Clin Immunol","first-page":"S41","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","unstructured":"Schroeder\n              HW\n              Jr,\n            \n            \n              Cavacini\n              L.\n            \n          \n          Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41\u2013S52."},{"key":"i2590-017X-8-1-34-b112","series-title":"Front. Immunol","first-page":"674","article-title":"Immunomodulation by IVIg and the role of Fc-Gamma Receptors: Classic Mechanisms of Action after all","volume":"5","author":"Nagelkerke","year":"2015","unstructured":"Nagelkerke\n              SQ,\n            \n            \n              Kuijpers\n              TW.\n            \n          \n          Immunomodulation by IVIg and the role of Fc-Gamma Receptors: Classic Mechanisms of Action after all? Front. Immunol. 2015;5:674."},{"key":"i2590-017X-8-1-34-b113","series-title":"Cells","first-page":"2417","article-title":"Anti-inflammatory and immunomodulatory effect of high-dose immunoglobulins in children: from approved indications to off-label use","volume":"12","author":"Conti","year":"2023","unstructured":"Conti\n              F,\n            \n            \n              Moratti\n              M,\n            \n            \n              Leonardi\n              L,\n            \n            et al.\n          \n          Anti-inflammatory and immunomodulatory effect of high-dose immunoglobulins in children: from approved indications to off-label use. Cells. 2023 Oct 7;12:2417.\u00a0"},{"key":"i2590-017X-8-1-34-b01","series-title":"Blood","first-page":"1727","article-title":"Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation","volume":"115","author":"Aubin","year":"2010","unstructured":"Aubin\n              \u00c9,\n            \n            \n              Lemieux\n              R,\n            \n            \n              Bazin\n              R.\n            \n          \n          Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood. 2010;115:1727\u20131734."},{"key":"i2590-017X-8-1-34-b02","series-title":"Front Immunol","first-page":"4","article-title":"Intravenous immunoglobulin and immunomodulation of B-cell\u2013in vitro and in vivo effects","volume":"6","author":"Mitrevski","year":"2015","unstructured":"Mitrevski\n              M,\n            \n            \n              Marrapodi\n              R,\n            \n            \n              Camponeschi\n              A,\n            \n            et al.\n          \n          Intravenous immunoglobulin and immunomodulation of B-cell\u2013in vitro and in vivo effects. Front Immunol. 2015;6:4."},{"key":"i2590-017X-8-1-34-b03","article-title":"Eight guiding principles for effective use of IVIG for patients with primary immunodeficiency","author":"American Academy of Allergy, Asthma, and Immunology","year":"2011","unstructured":"American Academy of Allergy, Asthma, and Immunology\n          . Eight guiding principles for effective use of IVIG for patients with primary immunodeficiency. 2011. Accessed Oct 1, 2024. www.aaaai.org\/Aaaai\/media\/Media-Library-PDFs\/Practice%20Management\/Practice%20Tools\/IVIG-guiding-principles.pdf"},{"key":"i2590-017X-8-1-34-b04","series-title":"J Clin Immunol","first-page":"1473","article-title":"Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee","volume":"42","author":"Tangye","year":"2022","unstructured":"Tangye\n              SG,\n            \n            \n              Al-Herz\n              W,\n            \n            \n              Bousfiha\n              A,\n            \n            et al.\n          \n          Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2022;42:1473\u2013507."},{"key":"i2590-017X-8-1-34-b05","series-title":"Front Immunol","first-page":"780134","article-title":"Implementation of early next-generation sequencing for inborn errors of immunity: a prospective observational cohort study of diagnostic yield and clinical implications in Dutch genome diagnostic centers","volume":"12","author":"Elsink","year":"2021","unstructured":"Elsink\n              K,\n            \n            \n              Huibers\n              MM,\n            \n            \n              Hollink\n              IH,\n            \n            et al.\n          \n          Implementation of early next-generation sequencing for inborn errors of immunity: a prospective observational cohort study of diagnostic yield and clinical implications in Dutch genome diagnostic centers. Front Immunol. 2021;12:780134."},{"key":"i2590-017X-8-1-34-b06","series-title":"J Clin Med","first-page":"4220","article-title":"Diagnostic challenges in patients with inborn errors of immunity with different manifestations of immune dysregulation","volume":"11","author":"Pieniawska-\u015amiech","year":"2022","unstructured":"Pieniawska-\u015amiech\n              K,\n            \n            \n              Pasternak\n              G,\n            \n            \n              Lewandowicz-Uszy\u0144ska\n              A,\n            \n            \n              Jutel\n              M.\n            \n          \n          Diagnostic challenges in patients with inborn errors of immunity with different manifestations of immune dysregulation. J Clin Med. 2022;11:4220."},{"key":"i2590-017X-8-1-34-b07","series-title":"J Clin Immunol","first-page":"727","article-title":"Helicobacter bilis-associated suppurative cholangitis in a patient with X-linked agammaglobulinemia","volume":"37","author":"Degand","year":"2017","unstructured":"Degand\n              N,\n            \n            \n              Dautremer\n              J,\n            \n            \n              Pilmis\n              B,\n            \n            et al.\n          \n          \n            Helicobacter bilis-associated suppurative cholangitis in a patient with X-linked agammaglobulinemia. J Clin Immunol. 2017;37:727\u2013731."},{"key":"i2590-017X-8-1-34-b08","series-title":"Clin Immunol","first-page":"21","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","unstructured":"Orange\n              JS,\n            \n            \n              Grossman\n              WJ,\n            \n            \n              Navickis\n              RJ,\n            \n            \n              Wilkes\n              MM.\n            \n          \n          Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21\u201330."},{"key":"i2590-017X-8-1-34-b09","series-title":"Ann Intern Med","first-page":"165","article-title":"The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial","volume":"135","author":"Eijkhout","year":"2001","unstructured":"Eijkhout\n              HW,\n            \n            \n              van der Meer\n              JW,\n            \n            \n              Kallenberg\n              CG,\n            \n            et al.\n          \n          The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001;135:165\u2013174."},{"key":"i2590-017X-8-1-34-b10","series-title":"J Allergy Clin Immunol","first-page":"210","article-title":"Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection","volume":"122","author":"Bonagura","year":"2008","unstructured":"Bonagura\n              VR,\n            \n            \n              Marchlewski\n              R,\n            \n            \n              Cox\n              A,\n            \n            \n              Rosenthal\n              DW.\n            \n          \n          Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122:210\u2013212."},{"key":"i2590-017X-8-1-34-b11","series-title":"J Clin Immunol","first-page":"1468","article-title":"A registry study of 240 patients with X-linked agammaglobulinemia living in the USA","volume":"43","author":"Hernandez-Trujillo","year":"2023","unstructured":"Hernandez-Trujillo\n              V,\n            \n            \n              Zhou\n              C,\n            \n            \n              Scalchunes\n              C,\n            \n            et al.\n          \n          A registry study of 240 patients with X-linked agammaglobulinemia living in the USA. J Clin Immunol. 2023;43:1468\u20131477."},{"key":"i2590-017X-8-1-34-b12","series-title":"Curr Opin Immunol","first-page":"176","article-title":"There is no gene for CVID\u2014novel monogenetic causes for primary antibody deficiency","volume":"72","author":"Ramirez","year":"2021","unstructured":"Ramirez\n              NJ,\n            \n            \n              Posadas-Cantera\n              S,\n            \n            \n              Caballero-Oteyza\n              A,\n            \n            et al.\n          \n          There is no gene for CVID\u2014novel monogenetic causes for primary antibody deficiency. Curr Opin Immunol. 2021;72:176\u2013185."},{"key":"i2590-017X-8-1-34-b13","series-title":"J Pediatr","first-page":"888","article-title":"Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation","volume":"154","author":"Urschel","year":"2009","unstructured":"Urschel\n              S,\n            \n            \n              Kayikci\n              L,\n            \n            \n              Wintergerst\n              U,\n            \n            et al.\n          \n          Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation. J Pediatr. 2009;154:888\u2013894."},{"key":"i2590-017X-8-1-34-b14","series-title":"Front Immunol","first-page":"637","article-title":"Persistent immune activation in CVID and the role of IVIg in its suppression","volume":"5","author":"Paquin-Proulx","year":"2014","unstructured":"Paquin-Proulx\n              D,\n            \n            \n              Sandberg\n              JK.\n            \n          \n          Persistent immune activation in CVID and the role of IVIg in its suppression. Front Immunol. 2014;5:637."},{"key":"i2590-017X-8-1-34-b15","series-title":"J Allergy Clin Immunol","first-page":"1354","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years","volume":"125","author":"Lucas","year":"2010","unstructured":"Lucas\n              M,\n            \n            \n              Lee\n              M,\n            \n            \n              Lortan\n              J,\n            \n            et al.\n          \n          Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125:1354\u20131360.e4."},{"key":"i2590-017X-8-1-34-b16","series-title":"Clin Exp Immunol","first-page":"172","article-title":"Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy","volume":"169","author":"Orange","year":"2012","unstructured":"Orange\n              J,\n            \n            \n              Belohradsky\n              B,\n            \n            \n              Berger\n              M,\n            \n            et al.\n          \n          Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169:172\u2013181."},{"key":"i2590-017X-8-1-34-b17","series-title":"Blood","first-page":"2718","article-title":"Immune reconstitution and survival of 100 SCID patients post\u2013hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","unstructured":"Heimall\n              J,\n            \n            \n              Logan\n              BR,\n            \n            \n              Cowan\n              MJ,\n            \n            et al.\n          \n          Immune reconstitution and survival of 100 SCID patients post\u2013hematopoietic cell transplant: a PIDTC natural history study. Blood. 2017;130:2718\u20132727."},{"key":"i2590-017X-8-1-34-b18","series-title":"Cell","first-page":"565","article-title":"Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2)","volume":"102","author":"Revy","year":"2000","unstructured":"Revy\n              P,\n            \n            \n              Muto\n              T,\n            \n            \n              Levy\n              Y,\n            \n            et al.\n          \n          Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000;102:565\u2013575."},{"key":"i2590-017X-8-1-34-b19","series-title":"J Trop Pediatr","first-page":"648","article-title":"X-linked hyper IgM syndrome manifesting as recurrent Pneumocystis jirovecii pneumonia: a case report","volume":"66","author":"Huang","year":"2020","unstructured":"Huang\n              SH,\n            \n            \n              Meng\n              XY,\n            \n            \n              Bai\n              ZJ,\n            \n            et al.\n          \n          X-linked hyper IgM syndrome manifesting as recurrent Pneumocystis jirovecii pneumonia: a case report. J Trop Pediatr. 2020;66:648\u2013654."},{"key":"i2590-017X-8-1-34-b20","series-title":"J Allergy Clin Immunol Pract","first-page":"1023","article-title":"Clinical phenotypes of hyper-IgM syndromes","volume":"4","author":"de la Morena","year":"2016","unstructured":"de la Morena\n              MT.\n            \n          \n          Clinical phenotypes of hyper-IgM syndromes. J Allergy Clin Immunol Pract. 2016;4:1023\u20131036."},{"key":"i2590-017X-8-1-34-b21","series-title":"Placenta","first-page":"36","article-title":"Expression of the neonatal Fc-receptor in placental-fetal endothelium and in cells of the placental immune system","volume":"78","author":"Kiskova","year":"2019","unstructured":"Kiskova\n              T,\n            \n            \n              Mytsko\n              Y,\n            \n            \n              Schepelmann\n              M,\n            \n            et al.\n          \n          Expression of the neonatal Fc-receptor in placental-fetal endothelium and in cells of the placental immune system. Placenta. 2019;78:36\u201343."},{"key":"i2590-017X-8-1-34-b22","series-title":"J Perinatol","first-page":"929","article-title":"Hypogammaglobulinemia in neonates: illustrative cases and review of the literature","volume":"44","author":"Darmawan","year":"2023","unstructured":"Darmawan\n              D,\n            \n            \n              Raychaudhuri\n              S,\n            \n            \n              Lakshminrusimha\n              S,\n            \n            \n              Dimitriades\n              VR.\n            \n          \n          Hypogammaglobulinemia in neonates: illustrative cases and review of the literature. J Perinatol. 2023;44:929\u2013934."},{"key":"i2590-017X-8-1-34-b23","author":"Justiz Vaillant","year":"2021","unstructured":"Justiz Vaillant\n              AA,\n            \n            \n              Wilson\n              AM.\n            \n          \n          Transient Hypogammaglobulinemia of Infancy. StatPearls Publishing; 2021."},{"key":"i2590-017X-8-1-34-b24","series-title":"Pediatr Rep","first-page":"e14","article-title":"Does intravenous immunoglobulin therapy prolong immunodeficiency in transient hypogammaglobulinemia of infancy","volume":"5","author":"Memmedova","year":"2013","unstructured":"Memmedova\n              L,\n            \n            \n              Azarsiz\n              E,\n            \n            \n              Karaca\n              NE,\n            \n            et al.\n          \n          Does intravenous immunoglobulin therapy prolong immunodeficiency in transient hypogammaglobulinemia of infancy? Pediatr Rep. 2013;5:e14."},{"key":"i2590-017X-8-1-34-b25","series-title":"J Clin Immunol","first-page":"158","article-title":"Prophylactic antibiotics versus immunoglobulin replacement in specific antibody deficiency","volume":"40","author":"Joud","year":"2020","unstructured":"Joud\n              H,\n            \n            \n              Nguyen\n              AL,\n            \n            \n              Constantine\n              G,\n            \n            et al.\n          \n          Prophylactic antibiotics versus immunoglobulin replacement in specific antibody deficiency. J Clin Immunol. 2020;40:158\u2013164."},{"key":"i2590-017X-8-1-34-b26","series-title":"J Clin Immunol","first-page":"382","article-title":"Immunoglobulin replacement therapy versus antibiotic prophylaxis as treatment for incomplete primary antibody deficiency","volume":"41","author":"Smits","year":"2021","unstructured":"Smits\n              BM,\n            \n            \n              Kleine Budde\n              I,\n            \n            \n              de Vries\n              E,\n            \n            et al.\n          \n          Immunoglobulin replacement therapy versus antibiotic prophylaxis as treatment for incomplete primary antibody deficiency. J Clin Immunol. 2021;41:382\u2013392."},{"key":"i2590-017X-8-1-34-b27","series-title":"Scand J Infect Dis","first-page":"44","article-title":"Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up","volume":"39","author":"Olinder-Nielsen","year":"2007","unstructured":"Olinder-Nielsen\n              AM,\n            \n            \n              Granert\n              C,\n            \n            \n              Forsberg\n              P,\n            \n            et al.\n          \n          Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up. Scand J Infect Dis. 2007;39:44\u201350."},{"issue":"2 Suppl 2","key":"i2590-017X-8-1-34-b28","series-title":"J Allergy Clin Immunol","first-page":"S195","article-title":"Secondary immunodeficiencies, including HIV infection","volume":"125","author":"Chinen","year":"2010","unstructured":"Chinen\n              J,\n            \n            \n              Shearer\n              WT.\n            \n          \n          Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S195\u2013S203."},{"key":"i2590-017X-8-1-34-b29","series-title":"Haematologica","first-page":"107","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","unstructured":"Blimark\n              C,\n            \n            \n              Holmberg\n              E,\n            \n            \n              Mellqvist\n              UH,\n            \n            et al.\n          \n          Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107\u2013113."},{"key":"i2590-017X-8-1-34-b30","series-title":"BMC Cancer","first-page":"1","article-title":"Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019","volume":"21","author":"Balmaceda","year":"2021","unstructured":"Balmaceda\n              N,\n            \n            \n              Aziz\n              M,\n            \n            \n              Chandrasekar\n              VT,\n            \n            et al.\n          \n          Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer. 2021;21:1\u201311."},{"key":"i2590-017X-8-1-34-b31","series-title":"Leukemia","first-page":"613","article-title":"Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients","volume":"36","author":"Caro","year":"2022","unstructured":"Caro\n              J,\n            \n            \n              Braunstein\n              M,\n            \n            \n              Williams\n              L,\n            \n            et al.\n          \n          Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. Leukemia. 2022;36:613\u2013624."},{"key":"i2590-017X-8-1-34-b32","series-title":"Blood Adv","first-page":"5898","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","unstructured":"Reynolds\n              G,\n            \n            \n              Cliff\n              ERS,\n            \n            \n              Mohyuddin\n              GR,\n            \n            et al.\n          \n          Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7:5898\u20135903."},{"key":"i2590-017X-8-1-34-b33","series-title":"Lancet","first-page":"1059","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma","volume":"343","author":"Chapel","year":"1994","unstructured":"Chapel\n              HM,\n            \n            \n              Lee\n              M,\n            \n            \n              Hargreaves\n              R,\n            \n            et al.\n          \n          Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet. 1994;343:1059\u20131063."},{"key":"i2590-017X-8-1-34-b34","series-title":"Leuk Lymphoma","first-page":"764","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","unstructured":"Raanani\n              P,\n            \n            \n              Gafter-Gvili\n              A,\n            \n            \n              Paul\n              M,\n            \n            et al.\n          \n          Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009;50:764\u2013772."},{"key":"i2590-017X-8-1-34-b35","series-title":"Lancet Haematol","first-page":"e143","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","unstructured":"Raje\n              NS,\n            \n            \n              Anaissie\n              E,\n            \n            \n              Kumar\n              SK,\n            \n            et al.\n          \n          Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9:e143\u2013e61."},{"key":"i2590-017X-8-1-34-b36","series-title":"Front Immunol","first-page":"1299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","unstructured":"Guo\n              Y,\n            \n            \n              Tian\n              X,\n            \n            \n              Wang\n              X,\n            \n            \n              Xiao\n              Z.\n            \n          \n          Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299."},{"key":"i2590-017X-8-1-34-b37","series-title":"Transpl Infect Dis","first-page":"679","article-title":"Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma","volume":"17","author":"Park","year":"2015","unstructured":"Park\n              S,\n            \n            \n              Jung\n              CW,\n            \n            \n              Jang\n              JH,\n            \n            et al.\n          \n          Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma. Transpl Infect Dis. 2015;17:679\u2013687."},{"key":"i2590-017X-8-1-34-b38","series-title":"Blood Cancer J","first-page":"116","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","unstructured":"Raje\n              N,\n            \n            \n              Anderson\n              K,\n            \n            \n              Einsele\n              H,\n            \n            et al.\n          \n          Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13:116."},{"key":"i2590-017X-8-1-34-b39","series-title":"Leuk Lymphoma","first-page":"18","article-title":"Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule","volume":"64","author":"Sim","year":"2023","unstructured":"Sim\n              B,\n            \n            \n              Ng\n              JY,\n            \n            \n              Teh\n              BW,\n            \n            \n              Talaulikar\n              D.\n            \n          \n          Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule. Leuk Lymphoma. 2023;64:18\u201329."},{"key":"i2590-017X-8-1-34-b40","series-title":"Curr Oncol Rep","first-page":"1003","article-title":"Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies","volume":"24","author":"Rivera","year":"2022","unstructured":"Rivera\n              D,\n            \n            \n              Ferrajoli\n              A.\n            \n          \n          Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies. Curr Oncol Rep. 2022;24:1003\u20131014."},{"key":"i2590-017X-8-1-34-b41","series-title":"Br J Haematol","first-page":"541","article-title":"Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia","volume":"159","author":"Oscier","year":"2012","unstructured":"Oscier\n              D,\n            \n            \n              Dearden\n              C,\n            \n            \n              Eren\n              E,\n            \n            et al.\n          \n          Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159:541\u2013564."},{"key":"i2590-017X-8-1-34-b42","series-title":"Hematol Transfus Cell Ther","first-page":"387","article-title":"Infections in patients with chronic lymphocytic leukemia","volume":"45","author":"Guarana","year":"2023","unstructured":"Guarana\n              M,\n            \n            \n              Nucci\n              M.\n            \n          \n          Infections in patients with chronic lymphocytic leukemia. Hematol Transfus Cell Ther. 2023;45:387\u2013393."},{"key":"i2590-017X-8-1-34-b43","series-title":"Cancer","first-page":"2883","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","unstructured":"Parikh\n              SA,\n            \n            \n              Leis\n              JF,\n            \n            \n              Chaffee\n              KG,\n            \n            et al.\n          \n          Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer. 2015;121:2883\u20132891."},{"key":"i2590-017X-8-1-34-b44","series-title":"N Engl J Med","first-page":"902","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial","volume":"319","author":"Gale","year":"1988","unstructured":"Gale\n              RP,\n            \n            \n              Chapel\n              HM,\n            \n            \n              Bunch\n              C,\n            \n            et al.\n          \n          Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319:902\u2013907."},{"key":"i2590-017X-8-1-34-b45","series-title":"N Engl J Med","first-page":"902","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial","volume":"319","author":"Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia","year":"1988","unstructured":"Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia, GaleRP,ChapelHM,et al.\n          Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319:902\u2013907."},{"key":"i2590-017X-8-1-34-b46","series-title":"Front Immunol","first-page":"317","article-title":"Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy","volume":"7","author":"S\u00e1nchez-Ram\u00f3n","year":"2016","unstructured":"S\u00e1nchez-Ram\u00f3n\n              S,\n            \n            \n              Dhalla\n              F,\n            \n            \n              Chapel\n              H.\n            \n          \n          Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy. Front Immunol. 2016;7:317."},{"key":"i2590-017X-8-1-34-b47","series-title":"Blood","first-page":"2745","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","unstructured":"Hallek\n              M,\n            \n            \n              Cheson\n              BD,\n            \n            \n              Catovsky\n              D,\n            \n            et al.\n          \n          iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u20132760."},{"key":"i2590-017X-8-1-34-b48","series-title":"Front Oncol","first-page":"1135812","article-title":"An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies","volume":"13","author":"Khan","year":"2023","unstructured":"Khan\n              S,\n            \n            \n              Allsup\n              D,\n            \n            \n              Molica\n              S.\n            \n          \n          An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies. Front Oncol. 2023;13:1135812."},{"key":"i2590-017X-8-1-34-b49","series-title":"Hematol Oncol Clin North Am","first-page":"827","article-title":"Can immunocompetence be restored in chronic lymphocytic leukemia","volume":"35","author":"Sun","year":"2021","unstructured":"Sun\n              C,\n            \n            \n              Wiestner\n              A.\n            \n          \n          Can immunocompetence be restored in chronic lymphocytic leukemia? Hematol Oncol Clin North Am. 2021;35:827\u2013845."},{"key":"i2590-017X-8-1-34-b50","series-title":"J Allergy Clin Immunol","first-page":"1525","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees","volume":"149","author":"Otani","year":"2022","unstructured":"Otani\n              IM,\n            \n            \n              Lehman\n              HK,\n            \n            \n              Jongco\n              AM,\n            \n            et al.\n          \n          Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees. J Allergy Clin Immunol. 2022;149:1525\u20131560."},{"key":"i2590-017X-8-1-34-b51","series-title":"Indian J Hematol Blood Transfus","first-page":"282","article-title":"Secondary hypogammaglobulinemia in patients with chronic lymphocytic leukemia receiving ibrutinib therapy","volume":"38","author":"\u00c7elik","year":"2022","unstructured":"\u00c7elik\n              S,\n            \n            \n              Kaynar\n              L,\n            \n            \n              G\u00fcven\n              ZT,\n            \n            et al.\n          \n          Secondary hypogammaglobulinemia in patients with chronic lymphocytic leukemia receiving ibrutinib therapy. Indian J Hematol Blood Transfus. 2022;38:282\u2013289."},{"key":"i2590-017X-8-1-34-b52","series-title":"Curr Oncol","first-page":"274","article-title":"A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and secondary antibody deficiency","volume":"30","author":"Visentin","year":"2022","unstructured":"Visentin\n              A,\n            \n            \n              Molinari\n              MC,\n            \n            \n              Pravato\n              S,\n            \n            et al.\n          \n          A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and secondary antibody deficiency. Curr Oncol. 2022;30:274\u2013283."},{"key":"i2590-017X-8-1-34-b53","series-title":"Immunotherapy","first-page":"713","article-title":"Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution","volume":"10","author":"Sacco","year":"2018","unstructured":"Sacco\n              KA,\n            \n            \n              Abraham\n              RS.\n            \n          \n          Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy. 2018;10:713\u2013728."},{"key":"i2590-017X-8-1-34-b54","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"106","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","unstructured":"Casulo\n              C,\n            \n            \n              Maragulia\n              J,\n            \n            \n              Zelenetz\n              AD.\n            \n          \n          Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13:106\u2013111."},{"key":"i2590-017X-8-1-34-b55","series-title":"J Allergy Clin Immunol","first-page":"1332","article-title":"Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations","volume":"148","author":"Thalhammer","year":"2021","unstructured":"Thalhammer\n              J,\n            \n            \n              Kindle\n              G,\n            \n            \n              Nieters\n              A,\n            \n            et al.\n          \n          Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. J Allergy Clin Immunol. 2021;148:1332\u20131341.e5."},{"key":"i2590-017X-8-1-34-b56","series-title":"JAMA Netw Open","first-page":"e184169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","unstructured":"Barmettler\n              S,\n            \n            \n              Ong\n              MS,\n            \n            \n              Farmer\n              JR,\n            \n            et al.\n          \n          Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1:e184169."},{"key":"i2590-017X-8-1-34-b57","series-title":"J Autoimmun","first-page":"24","article-title":"Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series","volume":"57","author":"Roberts","year":"2015","unstructured":"Roberts\n              DM,\n            \n            \n              Jones\n              RB,\n            \n            \n              Smith\n              RM,\n            \n            et al.\n          \n          Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun. 2015;57:24\u201329."},{"key":"i2590-017X-8-1-34-b58","series-title":"J Allergy Clin Immunol Pract","first-page":"460","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","unstructured":"Wat\n              J,\n            \n            \n              Barmettler\n              S.\n            \n          \n          Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions. J Allergy Clin Immunol Pract. 2022;10:460\u2013466."},{"key":"i2590-017X-8-1-34-b59","series-title":"Expert Rev Hematol","first-page":"305","article-title":"Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians","volume":"15","author":"Kampouri","year":"2022","unstructured":"Kampouri\n              E,\n            \n            \n              Walti\n              CS,\n            \n            \n              Gauthier\n              J,\n            \n            \n              Hill\n              JA.\n            \n          \n          Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Rev Hematol. 2022;15:305\u2013320."},{"key":"i2590-017X-8-1-34-b60","series-title":"Blood Adv","first-page":"2525","article-title":"Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1","volume":"3","author":"Ustun","year":"2019","unstructured":"Ustun\n              C,\n            \n            \n              Kim\n              S,\n            \n            \n              Chen\n              M,\n            \n            et al.\n          \n          Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. Blood Adv. 2019;3:2525\u20132536."},{"key":"i2590-017X-8-1-34-b61","series-title":"Blood","first-page":"3928","article-title":"The risk factors for IgG hypogammaglobulinemia after allogeneic hematopoietic stem cell transplantation and its impact on transplant outcomes","volume":"124","author":"Uhm","year":"2014","unstructured":"Uhm\n              J,\n            \n            \n              Hamad\n              N,\n            \n            \n              Gupta\n              V,\n            \n            et al.\n          \n          The risk factors for IgG hypogammaglobulinemia after allogeneic hematopoietic stem cell transplantation and its impact on transplant outcomes. Blood. 2014;124:3928."},{"key":"i2590-017X-8-1-34-b62","series-title":"Int J Hematol","first-page":"422","article-title":"Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy","volume":"112","author":"Mizuhara","year":"2020","unstructured":"Mizuhara\n              K,\n            \n            \n              Fujii\n              N,\n            \n            \n              Meguri\n              Y,\n            \n            et al.\n          \n          Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy. Int J Hematol. 2020;112:422\u2013426."},{"key":"i2590-017X-8-1-34-b63","series-title":"Bone Marrow Transplant","first-page":"267","article-title":"Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival","volume":"41","author":"Norlin","year":"2008","unstructured":"Norlin\n              A,\n            \n            \n              Sairafi\n              D,\n            \n            \n              Mattsson\n              J,\n            \n            et al.\n          \n          Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant. 2008;41:267\u2013273."},{"issue":"Suppl 1","key":"i2590-017X-8-1-34-b64","series-title":"Clin Exp Immunol","first-page":"43","article-title":"Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease","volume":"104","author":"Sullivan","year":"1996","unstructured":"Sullivan\n              KM.\n            \n          \n          Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. Clin Exp Immunol. 1996;104(Suppl 1):43\u201348."},{"issue":"Suppl 1","key":"i2590-017X-8-1-34-b65","series-title":"Clin Exp Immunol","first-page":"94","article-title":"Intravenous immunoglobulin and immune response","volume":"178","author":"Kaveri","year":"2014","unstructured":"Kaveri\n              S,\n            \n            \n              Lecerf\n              M,\n            \n            \n              Saha\n              C,\n            \n            et al.\n          \n          Intravenous immunoglobulin and immune response. Clin Exp Immunol. 2014;178(Suppl 1):94."},{"key":"i2590-017X-8-1-34-b66","series-title":"N Engl J Med","first-page":"2565","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","unstructured":"Zeiser\n              R,\n            \n            \n              Blazar\n              BR.\n            \n          \n          Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565\u20132579."},{"key":"i2590-017X-8-1-34-b67","series-title":"Front Immunol","first-page":"578314","article-title":"New approaches for the treatment of chronic graft-versus-host disease: current status and future directions","volume":"11","author":"Saidu","year":"2020","unstructured":"Saidu\n              NEB,\n            \n            \n              Bonini\n              C,\n            \n            \n              Dickinson\n              A,\n            \n            et al.\n          \n          New approaches for the treatment of chronic graft-versus-host disease: current status and future directions. Front Immunol. 2020;11:578314."},{"key":"i2590-017X-8-1-34-b68","series-title":"J Natl Compr Canc Netw","first-page":"599","article-title":"Hematopoietic cell transplantation, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Saad","year":"2020","unstructured":"Saad\n              A,\n            \n            \n              de Lima\n              M,\n            \n            \n              Anand\n              S,\n            \n            et al.\n          \n          Hematopoietic cell transplantation, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:599\u2013634."},{"key":"i2590-017X-8-1-34-b69","series-title":"Am J Transplant","first-page":"1157","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","unstructured":"Wiebe\n              C,\n            \n            \n              Gibson\n              I,\n            \n            \n              Blydt-Hansen\n              T,\n            \n            et al.\n          \n          Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157\u20131167."},{"key":"i2590-017X-8-1-34-b70","series-title":"Transplantation","first-page":"887","article-title":"Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients","volume":"70","author":"Montgomery","year":"2000","unstructured":"Montgomery\n              RA,\n            \n            \n              Zachary\n              AA,\n            \n            \n              Racusen\n              LC,\n            \n            et al.\n          \n          Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70:887\u2013895."},{"key":"i2590-017X-8-1-34-b71","series-title":"Sci Rep","first-page":"7682","article-title":"Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients","volume":"13","author":"Kim","year":"2023","unstructured":"Kim\n              HW,\n            \n            \n              Lee\n              J,\n            \n            \n              Heo\n              S-J,\n            \n            et al.\n          \n          Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients. Sci Rep. 2023;13:7682."},{"key":"i2590-017X-8-1-34-b72","series-title":"Am J Transplant","first-page":"255","article-title":"Diagnosis and management of antibody-mediated rejection: current status and novel approaches","volume":"14","author":"Djamali","year":"2014","unstructured":"Djamali\n              A,\n            \n            \n              Kaufman\n              D,\n            \n            \n              Ellis\n              T,\n            \n            et al.\n          \n          Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant. 2014;14:255\u2013271."},{"key":"i2590-017X-8-1-34-b73","series-title":"Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection: A Review of Clinical Effectiveness. CADTH Rapid Response Reports","author":"Khangura","year":"2018","unstructured":"Khangura\n              SD,\n            \n            \n              Visintini\n              S.\n            \n          \n          \n            Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection: A Review of Clinical Effectiveness. CADTH Rapid Response Reports\n          . Ottawa, Ontario, Canada: Canadian Agency for Drugs and Technologies in Health; 2018."},{"issue":"Suppl 1","key":"i2590-017X-8-1-34-b74","series-title":"Transfus Med Rev","first-page":"S1","article-title":"Guidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation","volume":"24","author":"Nahirniak","year":"2010","unstructured":"Nahirniak\n              S,\n            \n            \n              Hume\n              HA.\n            \n          \n          Guidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation. Transfus Med Rev. 2010;24(Suppl 1):S1\u2013S6."},{"key":"i2590-017X-8-1-34-b75","series-title":"BMC Nephrology","first-page":"218","article-title":"Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection","volume":"20","author":"Sablik","year":"2019","unstructured":"Sablik\n              KA,\n            \n            \n              Clahsen-van Groningen\n              MC,\n            \n            \n              Looman\n              CWN,\n            \n            et al.\n          \n          Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection. BMC Nephrology. 2019;20:218."},{"issue":"1","key":"i2590-017X-8-1-34-b76","series-title":"BMC Nephrology","first-page":"9","article-title":"Treatment of chronic active antibody-mediated rejection in renal transplant recipients\u2013a single center retrospective study","volume":"21","author":"Chiu","year":"2020","unstructured":"Chiu\n              H-F,\n            \n            \n              Wen\n              M-C,\n            \n            \n              Wu\n              M-J,\n            \n            et al.\n          \n          Treatment of chronic active antibody-mediated rejection in renal transplant recipients\u2013a single center retrospective study. BMC Nephrology. 2020;21:1\u20139."},{"key":"i2590-017X-8-1-34-b77","series-title":"N Engl J Med","first-page":"945","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","unstructured":"Cooper\n              N,\n            \n            \n              Ghanima\n              W.\n            \n          \n          Immune thrombocytopenia. N Engl J Med. 2019;381:945\u2013955."},{"key":"i2590-017X-8-1-34-b78","series-title":"Lancet","first-page":"1228","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","unstructured":"Imbach\n              P,\n            \n            \n              Barandun\n              S,\n            \n            \n              d\u2019Apuzzo\n              V,\n            \n            et al.\n          \n          High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228\u20131231."},{"key":"i2590-017X-8-1-34-b79","series-title":"Transfus Med","first-page":"48","article-title":"Efficacy and safety of a new intravenous immunoglobulin (Panzyga(I)) in chronic immune thrombocytopenia","volume":"29","author":"Arbach","year":"2019","unstructured":"Arbach\n              O,\n            \n            \n              Taumberger\n              AB,\n            \n            \n              Wietek\n              S,\n            \n            et al.\n          \n          Efficacy and safety of a new intravenous immunoglobulin (Panzyga(I)) in chronic immune thrombocytopenia. Transfus Med. 2019;29:48\u201354."},{"key":"i2590-017X-8-1-34-b80","series-title":"Eur J Haematol","first-page":"531","article-title":"Autoimmune thrombocytopenia: current treatment options in adults with a focus on novel drugs","volume":"103","author":"Witkowski","year":"2019","unstructured":"Witkowski\n              M,\n            \n            \n              Witkowska\n              M,\n            \n            \n              Robak\n              T.\n            \n          \n          Autoimmune thrombocytopenia: current treatment options in adults with a focus on novel drugs. Eur J Haematol. 2019;103:531\u2013541."},{"key":"i2590-017X-8-1-34-b81","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"400","article-title":"Management of newly diagnosed immune thrombocytopenia: can we change outcomes","volume":"2017","author":"Neunert","year":"2017","unstructured":"Neunert\n              CE.\n            \n          \n          Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Hematology Am Soc Hematol Educ Program. 2017;2017:400\u2013405."},{"key":"i2590-017X-8-1-34-b82","series-title":"N Engl J Med","first-page":"647","article-title":"Warm autoimmune hemolytic anemia","volume":"381","author":"Brodsky","year":"2019","unstructured":"Brodsky\n              RA.\n            \n          \n          Warm autoimmune hemolytic anemia. N Engl J Med. 2019;381:647\u2013654."},{"key":"i2590-017X-8-1-34-b83","series-title":"Blood Rev","first-page":"100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","unstructured":"J\u00e4ger\n              U,\n            \n            \n              Barcellini\n              W,\n            \n            \n              Broome\n              CM,\n            \n            et al.\n          \n          Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648."},{"key":"i2590-017X-8-1-34-b84","series-title":"Autoimmun Rev","first-page":"264","article-title":"Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia","volume":"4","author":"Mouthon","year":"2005","unstructured":"Mouthon\n              L,\n            \n            \n              Guillevin\n              L,\n            \n            \n              Tellier\n              Z.\n            \n          \n          Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev. 2005;4:264\u2013269."},{"key":"i2590-017X-8-1-34-b85","series-title":"N Engl J Med","first-page":"519","article-title":"Pure red-cell aplasia of 10 ye\u2019rs' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy","volume":"321","author":"Kurtzman","year":"1989","unstructured":"Kurtzman\n              G,\n            \n            \n              Frickhofen\n              N,\n            \n            \n              Kimball\n              J,\n            \n            et al.\n          \n          Pure red-cell aplasia of 10 ye\u2019rs' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med. 1989;321:519\u2013523."},{"key":"i2590-017X-8-1-34-b86","series-title":"Transplantation","first-page":"1847","article-title":"Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin","volume":"64","author":"Moudgil","year":"1997","unstructured":"Moudgil\n              A,\n            \n            \n              Shidban\n              H,\n            \n            \n              Nast\n              CC,\n            \n            et al.\n          \n          Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation. 1997;64:1847\u20131850."},{"key":"i2590-017X-8-1-34-b87","series-title":"Am J Hematol","first-page":"16","article-title":"Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin\u2013a report of eight patients","volume":"61","author":"Koduri","year":"1999","unstructured":"Koduri\n              PR,\n            \n            \n              Kumapley\n              R,\n            \n            \n              Valladares\n              J,\n            \n            \n              Teter\n              C.\n            \n          \n          Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin\u2013a report of eight patients. Am J Hematol. 1999;61:16\u201320."},{"key":"i2590-017X-8-1-34-b88","series-title":"Front Med","first-page":"1208418","article-title":"Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience","volume":"10","author":"Merli","year":"2023","unstructured":"Merli\n              M,\n            \n            \n              Accorinti\n              M,\n            \n            \n              Romagnuolo\n              M,\n            \n            et al.\n          \n          Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience. Front Med. 2023;10:1208418."},{"key":"i2590-017X-8-1-34-b89","series-title":"J Immunother","first-page":"276","article-title":"Immune checkpoint inhibitor\u2013related Guillain-Barr\u00e9 syndrome: a case series and review of the literature","volume":"44","author":"Janssen","year":"2021","unstructured":"Janssen\n              JB,\n            \n            \n              Leow\n              TY,\n            \n            \n              Herbschleb\n              KH,\n            \n            et al.\n          \n          Immune checkpoint inhibitor\u2013related Guillain-Barr\u00e9 syndrome: a case series and review of the literature. J Immunother. 2021;44:276\u2013282."},{"key":"i2590-017X-8-1-34-b90","series-title":"J Immunother Cancer","first-page":"1","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","unstructured":"Safa\n              H,\n            \n            \n              Johnson\n              DH,\n            \n            \n              Trinh\n              VA,\n            \n            et al.\n          \n          Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7:1\u201311."},{"key":"i2590-017X-8-1-34-b91","series-title":"Front Immunol","first-page":"1275254","article-title":"Immune checkpoint inhibitor\u2013associated myocarditis: a systematic analysis of case reports","volume":"14","author":"Wang","year":"2023","unstructured":"Wang\n              C,\n            \n            \n              Zhao\n              G,\n            \n            \n              Zhang\n              Z,\n            \n            et al.\n          \n          Immune checkpoint inhibitor\u2013associated myocarditis: a systematic analysis of case reports. Front Immunol. 2023;14:1275254."},{"key":"i2590-017X-8-1-34-b92","series-title":"Curr Rheumatol Rep","first-page":"1","article-title":"Immune checkpoint inhibitor-induced myositis: a case report and literature review","volume":"21","author":"Kadota","year":"2019","unstructured":"Kadota\n              H,\n            \n            \n              Gono\n              T,\n            \n            \n              Shirai\n              Y,\n            \n            et al.\n          \n          Immune checkpoint inhibitor-induced myositis: a case report and literature review. Curr Rheumatol Rep. 2019;21:1\u20139."},{"key":"i2590-017X-8-1-34-b93","series-title":"J Immunother Cancer","first-page":"e002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","unstructured":"Brahmer\n              JR,\n            \n            \n              Abu-Sbeih\n              H,\n            \n            \n              Ascierto\n              PA,\n            \n            et al.\n          \n          Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:e002435."},{"key":"i2590-017X-8-1-34-b94","series-title":"Respir Med Case Rep","first-page":"100834","article-title":"Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: case report and review of the literature","volume":"27","author":"Petri","year":"2019","unstructured":"Petri\n              CR,\n            \n            \n              Patell\n              R,\n            \n            \n              Batalini\n              F,\n            \n            et al.\n          \n          Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: case report and review of the literature. Respir Med Case Rep. 2019;27:100834."},{"key":"i2590-017X-8-1-34-b95","series-title":"Anticancer Drugs","first-page":"e738","article-title":"Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis","volume":"33","author":"Kian","year":"2022","unstructured":"Kian\n              W,\n            \n            \n              Zemel\n              M,\n            \n            \n              Elobra\n              F,\n            \n            et al.\n          \n          Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis. Anticancer Drugs. 2022;33:e738\u2013e40."},{"key":"i2590-017X-8-1-34-b96","series-title":"Neurology","first-page":"419","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","unstructured":"Sanders\n              DB,\n            \n            \n              Wolfe\n              GI,\n            \n            \n              Benatar\n              M,\n            \n            et al.\n          \n          International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87:419\u2013425."},{"key":"i2590-017X-8-1-34-b97","series-title":"Ann N Y Acad Sci","first-page":"720","article-title":"Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis","volume":"841","author":"Gajdos","year":"1998","unstructured":"Gajdos\n              P,\n            \n            \n              Chevret\n              S,\n            \n            \n              Clair\n              B,\n            \n            et al.\n          \n          Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. Ann N Y Acad Sci. 1998;841:720\u2013726."},{"issue":"12","key":"i2590-017X-8-1-34-b98","series-title":"Cochrane Database Syst Rev","first-page":"CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Eftimov","year":"2013","unstructured":"Eftimov\n              F,\n            \n            \n              Winer\n              JB,\n            \n            \n              Vermeulen\n              M,\n            \n            et al.\n          \n          Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;(12):CD001797."},{"key":"i2590-017X-8-1-34-b99","series-title":"Eur J Dermatol","first-page":"90","article-title":"European Dermatology Forum Guideline Subcommittee. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology","volume":"19","author":"Enk","year":"2009","unstructured":"Enk\n              A\n            \n          , European Dermatology Forum Guideline Subcommittee. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol. 2009;19:90\u201398."},{"key":"i2590-017X-8-1-34-b100","series-title":"Int J Rheum Dis","first-page":"64","article-title":"Role of intravenous immunoglobulin in the treatment of Kawasaki disease","volume":"21","author":"Lo","year":"2018","unstructured":"Lo\n              MS,\n            \n            \n              Newburger\n              JW.\n            \n          \n          Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis. 2018;21:64\u201369."},{"key":"i2590-017X-8-1-34-b101","series-title":"J Dermatol Sci","first-page":"77","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","unstructured":"Amagai\n              M,\n            \n            \n              Ikeda\n              S,\n            \n            \n              Hashimoto\n              T,\n            \n            et al.\n          \n          A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J Dermatol Sci. 2017;85:77\u201384."},{"key":"i2590-017X-8-1-34-b102","series-title":"Ann Rheum Dis","first-page":"1583","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","unstructured":"Yates\n              M,\n            \n            \n              Watts\n              RA,\n            \n            \n              Bajema\n              I,\n            \n            et al.\n          \n          EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583\u20131594."},{"key":"i2590-017X-8-1-34-b103","series-title":"Rheumatology","first-page":"646","article-title":"Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion","volume":"47","author":"Perricone","year":"2008","unstructured":"Perricone\n              R,\n            \n            \n              De Carolis\n              C,\n            \n            \n              Kr\u00f6egler\n              B,\n            \n            et al.\n          \n          Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology. 2008;47:646\u2013651."},{"key":"i2590-017X-8-1-34-b104","series-title":"Front Immunol","first-page":"740517","article-title":"A retrospective observational study of adverse reactions associated with intravenous immunoglobulin infusion","volume":"12","author":"Kato","year":"2021","unstructured":"Kato\n              H,\n            \n            \n              Hayashi\n              M,\n            \n            \n              Ohashi\n              W,\n            \n            et al.\n          \n          A retrospective observational study of adverse reactions associated with intravenous immunoglobulin infusion. Front Immunol. 2021;12:740517."},{"key":"i2590-017X-8-1-34-b105","series-title":"Am J Health-Syst Pharm","first-page":"1415","article-title":"Immune globulin therapy and kidney disease: overview and screening, monitoring, and management recommendations","volume":"79","author":"Kobayashi","year":"2022","unstructured":"Kobayashi\n              RH,\n            \n            \n              Rigas\n              MT.\n            \n          \n          Immune globulin therapy and kidney disease: overview and screening, monitoring, and management recommendations. Am J Health-Syst Pharm. 2022;79:1415\u20131423."},{"key":"i2590-017X-8-1-34-b106","series-title":"PLoS One","first-page":"e0265852","article-title":"Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles","volume":"17","author":"Abbott","year":"2022","unstructured":"Abbott\n              JK,\n            \n            \n              Chan\n              SK,\n            \n            \n              MacBeth\n              M,\n            \n            et al.\n          \n          Fluctuations in quality of life and immune responses during intravenous immunoglobulin infusion cycles. PLoS One. 2022;17:e0265852."},{"key":"i2590-017X-8-1-34-b107","series-title":"J Am Acad Dermatol","first-page":"AB45","article-title":"Eczematous skin reaction after intravenous immunoglobulin (IVIG) therapy","volume":"72","author":"Zhang","year":"2015","unstructured":"Zhang\n              J,\n            \n            \n              Cusack\n              CA.\n            \n          \n          Eczematous skin reaction after intravenous immunoglobulin (IVIG) therapy. J Am Acad Dermatol. 2015;72:AB45."},{"key":"i2590-017X-8-1-34-b108","series-title":"Clin Exp Immunol","first-page":"384","article-title":"Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study","volume":"206","author":"Martinez","year":"2021","unstructured":"Martinez\n              C,\n            \n            \n              Wallenhorst\n              C,\n            \n            \n              van Nunen\n              S.\n            \n          \n          Intravenous immunoglobulin and the current risk of moderate and severe anaphylactic events, a cohort study. Clin Exp Immunol. 2021;206:384\u2013394."},{"key":"i2590-017X-8-1-34-b109","series-title":"Clin Rheumatol","first-page":"541","article-title":"Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review","volume":"39","author":"Baudel","year":"2020","unstructured":"Baudel\n              JL,\n            \n            \n              Vigneron\n              C,\n            \n            \n              Pras-Landre\n              V,\n            \n            et al.\n          \n          Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review. Clin Rheumatol. 2020;39:541\u2013546."},{"key":"i2590-017X-8-1-34-b110","series-title":"Autoimmun Rev","first-page":"71","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence","volume":"15","author":"Cherin","year":"2016","unstructured":"Cherin\n              P,\n            \n            \n              Marie\n              I,\n            \n            \n              Michallet\n              M,\n            \n            et al.\n          \n          Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15:71\u201381."},{"issue":"2","key":"i2590-017X-8-1-34-b111","series-title":"J Allergy Clin Immunol","first-page":"S41","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","unstructured":"Schroeder\n              HW\n              Jr,\n            \n            \n              Cavacini\n              L.\n            \n          \n          Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41\u2013S52."},{"key":"i2590-017X-8-1-34-b112","series-title":"Front. Immunol","first-page":"674","article-title":"Immunomodulation by IVIg and the role of Fc-Gamma Receptors: Classic Mechanisms of Action after all","volume":"5","author":"Nagelkerke","year":"2015","unstructured":"Nagelkerke\n              SQ,\n            \n            \n              Kuijpers\n              TW.\n            \n          \n          Immunomodulation by IVIg and the role of Fc-Gamma Receptors: Classic Mechanisms of Action after all? Front. Immunol. 2015;5:674."},{"key":"i2590-017X-8-1-34-b113","series-title":"Cells","first-page":"2417","article-title":"Anti-inflammatory and immunomodulatory effect of high-dose immunoglobulins in children: from approved indications to off-label use","volume":"12","author":"Conti","year":"2023","unstructured":"Conti\n              F,\n            \n            \n              Moratti\n              M,\n            \n            \n              Leonardi\n              L,\n            \n            et al.\n          \n          Anti-inflammatory and immunomodulatory effect of high-dose immunoglobulins in children: from approved indications to off-label use. Cells. 2023 Oct 7;12:2417.\u00a0"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"link":[{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/8\/1\/article-p34.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/8\/1\/34\/3479794\/10.36401_jipo-24-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/8\/1\/article-p34.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/8\/1\/article-p34.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:44:33Z","timestamp":1771634673000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/8\/1\/article-p34.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":226,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.36401\/jipo-24-7","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}